ACP 211
Alternative Names: ACP-211Latest Information Update: 31 Mar 2025
At a glance
- Originator ACADIA Pharmaceuticals
- Class Antidepressants
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Major depressive disorder
Most Recent Events
- 26 Feb 2025 Phase-I clinical trials in Major depressive disorder (unspecified route) before February 2025 (Acadia Pharmaceutical pipeline, February 2025)